FINAL RESULTS OF THE INSPIRE TRIAL WITH THE NOVEL MGUARD STENT SYSTEM CONTAINING A PROTECTION NET TO PREVENT DISTAL EMBOLIZATION  by de Ribamar Costa, Jose et al.
    
 i2 SUMMIT   
A180.E1680 
JACC March 9, 2010
Volume 55, issue 10A
FINAL RESULTS OF THE INSPIRE TRIAL WITH THE NOVEL MGUARD STENT SYSTEM CONTAINING A 
PROTECTION NET TO PREVENT DISTAL EMBOLIZATION
i2 Oral Contributions
Georgia World Congress Center, Room B315
Sunday, March 14, 2010, 4:42 p.m.-4:54 p.m.
Session Title: New Technologies
Abstract Category: New Technologies/Innovations
Presentation Number: 2904-06
Authors: Jose de Ribamar Costa, Jr., Alexandre Abizaid, Ricardo Costa, Felipe Maia, Fausto Feres, Rodolfo Staico, Dimytri Siqueira, Galo Maldonado, 
Luiz Fernando Tanajura, Renata Viana, Juliana Castro, Amanda Sousa, J Eduardo Sousa, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil, 
Cardiovascular Research Center, São Paulo, Brazil
Background: Disturbances of coronary flow due to distal embolization of thrombus/platelet agreggates are associated with worse immediate and 
long-term prognosis after PCI. Treatment of SVG and PCI in the setting of acute coronary syndromes (ACS) are often related to this complication. 
Although protection devices (filterwires) have been shown to reduce distal embolization, they add time and cost to PCI. The newly developed 
balloon-expandable Mguard stent system is a combination of an ultra-thin polymer mesh sleeve attached to the external surface of a BMS designed 
to provide embolic protection during PCI.
Methods: A total of 30 pts were enrolled. Inclusion critiria was de novo lesions in SVG or native vessels with angiographic evidence of instability 
with potential to provoke flow disturbances and/or distal embolization. Primary endpoint was the incidence of MACE (composite of cardiac death, 
non-fatal MI and TLR) up to 30 days of the procedure. Secondary endpoints included in-stent late lumen loss (QCA), % of stent obstruction (IVUS) at 
6 months and combined up to 1 year. QCA and IVUS were performed by independent corelabs.
Results: Mean population age was 63 years with 38% of diabetics. Overall, 55% presented with ACS and 57% of lesions were located in SVG. Most 
lesions had complex morphology including the presence of thrombus (26%) and ulceration (20%). Distal/proximal protection devices were not used. 
Preprocedural QCA data showed lesion length and reference vessel diameter of 12.0±4.5mm and 3.0±0.5mm. The Mguard stent was successfully 
delivered in all cases and final TIMI-3 was achieved in 100% with no MACE up to 30 days. At 6 months, in-stent late loss and % of stent obstruction 
were 1.0 ± 0.4mm and 28.5±15.6%. Up to one year clinical follow-up there was no case of cardiac death, one Q-wave MI and 6 cases of ischemia-
driven TLR. Also, there was a single case of definite/probable stent thorombosis.
Conclusions: The MGuard stent demonstrated excellent acute performance in a highly complex lesion subset with no adverse events up to 30 
days. No further safety concerns were observed up to the 1st year of the procedure. Conversily, efficacy of the novel device was equivalent to other 
BMS in similar complex scenarios.
